In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against gram-positive and gram-negative organisms

被引：66

作者：

Almer, LS ^{[1
]}

Hoffrage, JB ^{[1
]}

Keller, EL ^{[1
]}

Flamm, RK ^{[1
]}

Shortridge, VD ^{[1
]}

机构：

[1] Abbott Labs, Abbott Pk, IL 60064 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 07期

关键词：

D O I：

10.1128/AAC.48.7.2771-2777.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 [微生物学]; 100705 [微生物与生化药学];

摘要：

In vitro activities of ABT-492, ciprofloxacin, levofloxacin, trovafloxacin, moxifloxacin, gatifloxacin, and gemifloxacin were compared. ABT-492 was more potent against quinolone-susceptible and -resistant gram-positive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms. Bactericidal activity of ABT-492 was also evaluated.

引用

收藏

页码：2771 / 2777

页数：7

相关论文

共 26 条

[1]

Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus [J].

Almer, LS ;

Shortridge, VD ;

Nilius, AM ;

Beyer, JM ;

Soni, NB ;

Bui, MH ;

Stone, GG ;

Flamm, RK .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 43 (03) :225-232

[2]

[Anonymous], PERF STAND ANT SUSC

[3]

Fluoroquinolone-resistant Haemophilus influenzae:: Frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America) [J].

Biedenbach, DJ ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (04) :255-259

[4]

Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms [J].

Blondeau, JM ;

Laskowski, R ;

Bjarnason, J ;

Stewart, C .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 14 (01) :45-50

[5]

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995 [J].

Brueggemann, AB ;

Coffman, SL ;

Rhomberg, P ;

Huynh, H ;

Almer, L ;

Nilius, A ;

Flamm, R ;

Doern, GV .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :680-688

[6]

In vitro antibacterial activity and phamacodynamics of new quinolones [J].

Dalhoff, A ;

Schmitz, FJ .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2003, 22 (04) :203-221

[7]

Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000) [J].

Davies, TA ;

Goldschmidt, R ;

Pfleger, S ;

Loeloff, M ;

Bush, K ;

Sahm, DF ;

Evangelista, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (02) :168-175

[8]

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995 [J].

Doern, GV ;

Heilmann, KP ;

Huynh, HK ;

Rhomberg, PR ;

Coffman, SL ;

Brueggemann, AB .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1721-1729

[9]

Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: A nationwide analysis [J].

Gupta, K ;

Sahm, DF ;

Mayfield, D ;

Stamm, WE .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (01) :89-94

[10]

Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study [J].

Hoban, D ;

Waites, K ;

Felmingham, D .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 45 (04) :251-259